I had the opportunity to chat with Dr. Ingmar Gorman, a co-founder of Fluence, about his psychedelic education company that is focused on training mental health providers in psychedelic treatments. As a psychologist, he shares his expertise in empirically supported psychedelic treatments with his clients and trainees alike.
He simultaneously served as site co-principal investigator on an FDA-approved Phase 3 clinical trial of MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder and is currently a study therapist on the same study, as well as another FDA-approved clinical trial of psilocybin for treatment-resistant depression. Dr. Gorman has published on the topics of classic psychedelics, ketamine, MDMA, and Psychedelic Harm Reduction and Integration.
